Premium
Transfer of EBV‐specific CTL to prevent EBV lymphoma post bone marrow transplant
Author(s) -
Heslop Helen E.,
Perez Margot,
Benaim Ely,
Rochester Richard,
Brenner Malcolm K.,
Rooney Cliona M.
Publication year - 1999
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/(sici)1098-1101(1999)14:3<154::aid-jca9>3.0.co;2-k
Subject(s) - medicine , ctl* , lymphoma , epstein–barr virus , immunology , bone marrow transplant , bone marrow , bone marrow transplantation , virology , virus , immune system , cd8
EBV‐associated lymphoproliferative disorders (EBV‐LPD) are a significant problem after hemopoietic stem cell transplantation from unrelated donors or mismatched family members. Risk factors include T‐cell depletion, MHC mismatch, and intensity of immunosuppression. New therapeutic strategies involve cellular immunotherapy approaches and both donor T‐cells and EBV‐specific cytotoxic T lymphocytes (CTLs) have proven to be effective therapies. EBV‐specific CTL has also proved to have a major impact on the incidence of this complication when used prophylactically. J. Clin. Apheresis 14:154–156, 1999. © 1999 Wiley‐Liss, Inc.